Publikationen in Zusammenarbeit mit Forschern von AstraZeneca (United Kingdom) (1)

2024

  1. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

    PharmacoEconomics - Open